Role of neurogenesis in the treatment of schizophrenia

神经发生在精神分裂症治疗中的作用

• 批准号: 18390320
• 负责人: MINABE Yoshio
• 金额: $ 10.53万
• 依托单位: Kanazawa University (2007)Hamamatsu University School of Medicine (2006)
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18390320/
• 关键词: Schizophrenia; MRS; coeinitive function; neurogenesis; perogride; double-blind method; hippocampus; striatum; 神経細胞新生; ドパミン; 陰性症状

Method. Patients were included in the study if they: 1) were age 18-50 years, met the DSM-IV criteria for schizophrenia as assessed with the Structured Clinical Interview for DSM-IV, Research Version (SCID-RV); 2)were treated with a stable-dose of risperidone, raging 2 to 6mg, for more than 8 weeks; 3) had a score 〓15 on negative subscale items in Positive and Negative Syndrome Scale (PANSS), 4)had a minimum period of symptom stability, defined as no more than 20% change on consecutive ratings on PANSS for at lease 4 weeks. Subjects entered a 8-weeks, double-blind treatment phase during which they were randomly assigned to receive either pergolide or placebo, which was added to risperidone treatment. Pergolide was started at a daily dose of 250 μg for I week and increased to 750 μg from the second week, continuing for total of 8 weeks. The study medication and placebo were provided in identically appearing capsules. The PANSS was used to assess the severity of psychiatric symptoms, and … More the Quality of Life Scale (QLS) abbreviated version was used to measure general social functioning. Extrapyramidal symptoms, akathisia, and dyskinesia, were evaluated by the Simpson-Angus Rating Scale for Extrapyramidal Symptoms, the Barnes Akathisia Scale, and the Abnormal Involuntary Movement Scale. Estimates of premorbid and current intellectual functions were made by Japanese version of National Adult Reading Test(JART)and short form of Wechsler Adult Intelligence Scale-Revised(WAIS-R). Patients were tested on a comprehensive neuropsychological test battery: executive function, spatial working memory, sustained attention, verbal memory, verbal working memory, verbal fluency. Premorbid and current intellectual functions were measured at the baseline. Results. Twenty-six subjects were randomized to either pergolide or placebo (13 pergolide, 13 placebo; mean age t SD, 33.9 t 5.5 in pergolide, 37.2 ± 8.4 in placebo). Twenty-two subjects completed the entire protocol. No significant differences were noted between the PANSS total, positive scale, and negative scale scores between groups at baseline. Repeated-measures ANOVA revealed no significant differences between pergolide and placebo treatment groups during 8 weeks of the study with respect to PANSS total, PANSS positive, PANSS negative, and QLS scores. There were no statistically significant differences in change(from baseline to week 8)on any of the cognitive measures between the placebo and pergolide treated groups. Less

法如果患者：1）年龄在18-50岁之间，符合DSM-IV精神分裂症标准（使用DSM-IV研究版结构化临床访谈（SCID-RV）评估）; 2）接受稳定剂量的利培酮（2 - 6 mg）治疗8周以上; 3）阳性和阴性症状量表（PANSS）中阴性子量表项目评分≥ 15，4）症状稳定期最短，定义为至少4周PANSS连续评分变化不超过20%。受试者进入为期8周的双盲治疗期，在此期间，他们被随机分配接受培高利特或安慰剂，后者加入利培酮治疗。培高利特的起始日剂量为250 μg，持续1周，从第2周开始增加至750 μg，持续共8周。研究药物和安慰剂以外观相同的胶囊形式提供。PANSS用于评估精神症状的严重程度， ...更多信息 生活质量量表（QLS）的缩写版本用于测量一般的社会功能。通过锥体外系症状的Alfresson-Angus评定量表、巴恩斯静坐不能量表和异常不自主运动量表评价锥体外系症状、静坐不能和运动障碍。采用日本版的全国成人阅读测验（JART）和韦氏成人智力量表修订版（WAIS-R）对患病前和当前的智力功能进行评估。对患者进行全面的神经心理学测试：执行功能，空间工作记忆，持续注意力，言语记忆，言语工作记忆，言语流畅性。在基线时测量发病前和当前的智力功能。结果26例受试者被随机分配至培高利特组或安慰剂组（培高利特组13例，安慰剂组13例;平均年龄t SD，培高利特组33.9 ± 5.5，安慰剂组37.2 ± 8.4）。22例受试者完成了整个方案。基线时，两组PANSS总分、阳性量表和阴性量表评分之间无显著差异。重复测量方差分析显示，在8周的研究期间，培高利特治疗组和安慰剂治疗组之间在PANSS总分、PANSS阳性、PANSS阴性和QLS评分方面没有显着差异。安慰剂和培高利特治疗组之间任何认知指标的变化（从基线至第8周）均无统计学显著差异。少

项目成果

Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia

• DOI: 10.1073/pnas.0610765104
• 发表时间: 2007-02-20
• 期刊: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• 影响因子: 11.1
• 作者: Yamada, Kazuo;Gerber, David J.;Yoshikawa, Takeo
• 通讯作者: Yoshikawa, Takeo

Disruption of Reelin signaling attenuates methamphetatnine-induced hyperlocomotion

Reelin 信号传导的破坏可减弱甲基苯丙胺诱导的过度运动

• 发表时间: 2007
• 期刊: European Journal of Neuroscience 25
• 作者: Matsuzaki;H.;Minabe;Y.;et. al.
• 通讯作者: et. al.

Association between polymorphisms in the promoter region of the sialytransferase 8B (SIAT8B) gene and schizophrenia.

唾液酸转移酶 8B (SIAT8B) 基因启动子区域的多态性与精神分裂症之间的关联。

• 发表时间: 2006
• 期刊: Biol Psychiatry 59・7
• 作者: Arai M;Minabe Y 他
• 通讯作者: Minabe Y 他

Increased levels of serum soluble L-selectin in unmedicated patients with schizophrenia

• DOI: 10.1016/j.schres.2006.08.026
• 发表时间: 2007-01-01
• 期刊: SCHIZOPHRENIA RESEARCH
• 影响因子: 4.5
• 作者: Iwata, Yasuhide;Suzuki, Katsuaki;Mori, Norio
• 通讯作者: Mori, Norio

Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia.

精神分裂症 STOP (MAP6) 基因的遗传和表达分析。

• 发表时间: 2006
• 期刊: Schizophrenia Research 84
• 作者: Tamagaki C;Sedvall GC;Jonsson EG;Okugawa G;Hall H;Pauli S;Agartz I;Nakajima M;Yamada K;Arai M;Iwayama Y;Yoshitsugu K;Shimizu H
• 通讯作者: Shimizu H